Skip to content
lennox

Partner Treatment Library

Anti-Infective & Antiparasitic

Ivermectin / Mebendazole Capsules — 25 mg / 250 mg

A compounded 25 mg/250 mg dual-anthelmintic capsule.

Evidence brief in review

Common goals
The two ingredients cover different established antiparasitic contexts when separately indicated.
Best program fit
Fits only diagnosis-specific care where a qualified clinician can justify both ingredients and manage additive safety and interaction questions.
Format
Capsule · 25 mg ivermectin / 250 mg mebendazole

Partner education guide

Where this may fit in an offering.

The two ingredients cover different established antiparasitic contexts when separately indicated. One capsule may reduce pill burden if a clinician has a diagnosis-specific reason to use both. May fit specialist-led care for selected mixed or uncertain helminth contexts only when both ingredients are justified.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

  • The two ingredients cover different established antiparasitic contexts when separately indicated.
  • One capsule may reduce pill burden if a clinician has a diagnosis-specific reason to use both.
  • Exposure and follow-up testing can make the program measurable.

Program value

How it may support a program

  • May fit specialist-led care for selected mixed or uncertain helminth contexts only when both ingredients are justified.
  • Creates a structured checkpoint for travel history, interactions, hygiene, and reinfection prevention.

The exact 25 mg/250 mg combination is not FDA approved and has no product-matched outcome evidence. It must not be marketed for unsupported anti-infective, anticancer, antiviral, or wellness use.

02 / Program fit

Program and operational considerations.

01Administration format
Catalog format: Capsule · 25 mg ivermectin / 250 mg mebendazole. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency
Frequency is individualized around the exact formulation, individual goals, tolerability, and monitoring plan.
03Expected duration
No product-matched course is established. Duration must follow the organism, body weight, exposure history, and licensed-clinician plan.
04Practical considerations
May fit specialist-led care for selected mixed or uncertain helminth contexts only when both ingredients are justified.

03 / Suitability considerations

Who may be considered.

Who may be considered

  • A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
  • An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

  • May fit specialist-led care for selected mixed or uncertain helminth contexts only when both ingredients are justified.
  • Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

01

Common or temporary

  • Dizziness, sleepiness, nausea, diarrhea, abdominal discomfort, itching, rash, or fatigue can occur.
  • Reactions may also reflect the parasite being treated; the pattern differs between strongyloidiasis and onchocerciasis.
  • Abdominal pain, diarrhea, gas, nausea, vomiting, reduced appetite, rash, or dizziness can occur.
  • Symptoms may depend on the infection and the duration of treatment.

02

Serious or important

  • Rare neurotoxicity can include confusion, altered consciousness, seizures, coma, or death. Severe reactions are a concern with heavy Loa loa infection.
  • Severe rash, low blood pressure, liver-test abnormalities, serious allergic reaction, or worsening neurologic symptoms requires urgent assessment.
  • Rare serious reactions include severe allergy, hepatitis or abnormal liver tests, neutropenia or agranulocytosis, seizures, and severe skin reactions.
  • Mebendazole should not be combined with metronidazole because Stevens-Johnson syndrome or toxic epidermal necrolysis has been reported.

03

Avoid or use only with specialist input

  • Use without a supported diagnosis, veterinary products, self-treatment for viral illness, cancer, or general wellness, or an unverified compounded source.
  • Known hypersensitivity, suspected heavy Loa loa exposure without appropriate evaluation, pregnancy or breastfeeding without a risk-benefit review, or use in a child under 15 kg without specialist guidance.
  • Use without a supported parasitic diagnosis, general wellness use, cancer treatment, viral-illness treatment, or an unverified compounded source.
  • Known mebendazole allergy, concurrent metronidazole, pregnancy without a clinician-led risk-benefit review, or use in children younger than two without specialist direction.

04

Screening checklist

  • Confirm the suspected or proven parasite, travel and residence history, body weight, Loa loa exposure risk, pregnancy and breastfeeding status, liver and neurologic history, immune suppression, and all medicines including warfarin.
  • Verify the exact capsule strength and determine whether diagnostic testing and follow-up testing are needed for the organism.
  • Confirm the organism and exposure history, age, pregnancy status, liver history, blood disorders, current medicines including metronidazole, and whether household or hygiene measures are needed to prevent reinfection.
  • Verify whether the compounded capsule is intended to match a supported mebendazole regimen and whether longer use requires blood-count or liver monitoring.

05

When to refer

  • Altered mental status, seizure, severe weakness, breathing difficulty, syncope, severe rash, or signs of disseminated infection requires urgent medical care.
  • Possible Loa loa exposure, disseminated strongyloidiasis, major immune suppression, pregnancy, very low body weight, uncertain diagnosis, or treatment failure warrants specialist input.
  • Severe rash, mouth sores, fever, facial swelling, jaundice, unusual bruising, seizure, or signs of serious allergy requires urgent assessment.
  • Uncertain diagnosis, pregnancy, age under two, prolonged or high-dose use, recurrent infection, immune suppression, or treatment failure warrants specialist review.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

The ingredients have separate antiparasitic uses, but the fixed 25 mg/250 mg combination is not a universal deworming or anti-infective regimen.

01 / Human research

The clearest clinical signal

Ivermectin and mebendazole labeling supports different parasite-specific uses. No product-matched trial was identified for this compounded fixed-dose combination.

02 / Real-world reports

What people describe

People may value one capsule, but should understand that broader ingredient coverage does not replace diagnosis, weight-based decisions, or reinfection prevention.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Ivermectin neurotoxicity and Loa loa risk combine with mebendazole liver, blood-count, seizure, skin-reaction, pregnancy, and metronidazole-interaction concerns.

Does the research match this exact product?

No. Separate labels do not validate the fixed combination, strengths, or broad off-label use.

Research and regulatory context

Ivermectin and mebendazole labels support different organism-specific uses. No reviewed source establishes that this 25 mg/250 mg compounded combination improves outcomes or is appropriate without diagnosis-specific justification.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments